Fig 1: Biochemical characterization of anti-PD-L1 VHH(A) Schematic representation of anti-PD-L1 VHH consisting of IL-2 signal peptide, anti-PD-L1 single domain antibody, and His-tag. (B) ELISA analysis of an anti-PD-L1-positive single domain antibody. On day 6 posttransfection, 10 µg/sample of HEK-293F culture supernatant was collected for ELISA to identify positive clone #13 (OD 450 = 1). (C) Coomassie blue staining of anti-PD-L1 VHH, approximately 15 kDa. (D) ELISA detected anti-PD-L1-VHH and anti-PD-L1 positive antibodies (durvalumab) as controls. (E) Flow cytometry analysis of anti-PD-L1-VHH and duvalumab using LS174T cells as positive and CHO cells as negative cells. (F) ELISA analysis of different antibodies: negative antibody (human IgG isotype control, Invitrogen, cat #02–7102), positive antibody (goat anti-mouse PD-L1 antibody, R&D systems, cat# AF1019), durvalumab (Creative Biolabs, cat# TAB-417CQ), and anti-PD-L1-VHH using as primary antibodies, and recombinant mouse PD-L1 as coated antigen. (G) ELISA analysis of different antibodies: negative antibody, positive antibody, duvalumab, and anti-PD-L1-VHH using as primary antibodies, and recombinant human PD-L1 as coated antigen. The results are the averages of duplicates from three independent experiments. Data are the means ± SEM, N.S., not significant, **P < 0.01; ** P < 0.001 compared with the control.
Fig 2: Anti-hPD-L1 single domain antibody screeningELISA was performed using 1 µg of purified and quantified phage to pick up 16 positive clones (OD 450 = 1.20, black bars). The positive phages binders OD450=coated plate OD450-uncoated plate OD450. The results are the averages of duplicates from three independent experiments. Data are the means ± SEM.See also Fig. S1.
Supplier Page from Creative Biolabs for Anti-Human CD274 Recombinant Antibody (Durvalumab)